{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:24Z","timestamp":1793946504906,"version":"4.8.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jacadv.2026.102598","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:16:10Z","timestamp":1774466170000},"page":"102598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Abhinav","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8397-7949","authenticated-orcid":false,"given":"Amir","family":"Razaghizad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna R.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George L.","family":"Bakris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer B.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rury R.","family":"Holman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10075","key":"10.1016\/j.jacadv.2026.102598_bib1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","article-title":"Chronic kidney disease","volume":"389","author":"Webster","year":"2017","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.jacadv.2026.102598_bib2","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacadv.2026.102598_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1056\/NEJMoa1504347","article-title":"Excess mortality among persons with type 2 diabetes","volume":"373","author":"Tancredi","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102598_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1008862","article-title":"Diabetes mellitus, fasting glucose, and risk of cause-specific death","volume":"364","author":"Seshasai","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jacadv.2026.102598_bib6","first-page":"S103","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes\u20132019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1016\/j.jacadv.2026.102598_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacadv.2026.102598_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102598_bib9","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/dc17-1091","article-title":"Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial","volume":"40","author":"Sharma","year":"2017","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102598_bib10","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.2337\/dc16-1415","article-title":"Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS","volume":"39","author":"Cornel","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102598_bib11","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc19-2137","article-title":"The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study","volume":"43","author":"Wan","year":"2020","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102598_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102598_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ejhf.1170","article-title":"Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Seferovi\u0107","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102598_bib14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.cardfail.2019.05.007","article-title":"Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America","volume":"25","author":"Dunlay","year":"2019","journal-title":"J Card Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102598_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jcjd.2019.09.003","article-title":"Mechanisms by which glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce cardiovascular risk in adults with type 2 diabetes mellitus","volume":"44","author":"Sharma","year":"2020","journal-title":"Can J Diabetes"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102598_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ehf2.14601","article-title":"Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease","volume":"11","author":"Sharma","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102598_bib17","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc19-1079","article-title":"Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: insights from EXSCEL","volume":"43","author":"Standl","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102598_bib18","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc17-1778","article-title":"Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype","volume":"41","author":"Standl","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102598_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacadv.2026.102598_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102598_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102598_bib22","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacadv.2026.102598_bib23","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.jacadv.2026.102598_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004007","article-title":"Predictors of chronic kidney disease in type 2 diabetes","volume":"95","author":"De Cosmo","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102598_bib25","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jdiacomp.2016.10.030","article-title":"Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes","volume":"31","author":"Viazzi","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacadv.2026.102598_bib26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1007\/BF00400637","article-title":"The Verona diabetes study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality","volume":"38","author":"Muggeo","year":"1995","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102598_bib27","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.2337\/dc08-2151","article-title":"Higher levels of urinary albumin excretion within the normal range predict faster decline in glomerular filtration rate in diabetic patients","volume":"32","author":"Babazono","year":"2009","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102598_bib28","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2215\/CJN.08001109","article-title":"Associations of diet with albuminuria and kidney function decline","volume":"5","author":"Lin","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102598_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010546","article-title":"Albuminuria as a predictor of cardiovascular outcomes in patients with acute myocardial infarction","volume":"8","author":"Mok","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102598_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"Gerstein","year":"2001","journal-title":"JAMA"},{"issue":"7258","key":"10.1016\/j.jacadv.2026.102598_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.jacadv.2026.102598_bib32","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102598_bib33","first-page":"1","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"2","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102598_bib34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jacadv.2026.102598_bib35","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102598_bib36","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"10.1016\/j.jacadv.2026.102598_bib37","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102598_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102598_bib39","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jacadv.2026.102598_bib40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.jacadv.2026.102598_bib41","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"10193","key":"10.1016\/j.jacadv.2026.102598_bib42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102598_bib43","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102598_bib44","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.jacc.2019.01.029","article-title":"Prescription of glucagon-like peptide-1 receptor agonists by cardiologists","volume":"73","author":"Vaduganathan","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102598_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007649","article-title":"Early and chronic dipeptidyl-peptidase-iv inhibition and cardiovascular events in patients with type 2 diabetes mellitus after an acute coronary syndrome: a landmark analysis of the EXAMINE trial","volume":"7","author":"Sharma","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102598_bib46","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031586","article-title":"Primary and secondary cardiovascular and kidney prevention with canagliflozin: insights from the CANVAS program and CREDENCE trial","volume":"13","author":"Sharma","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102598_bib47","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11886-022-01715-3","article-title":"Synchronous health care delivery for the optimization of cardiovascular and renal care in patients with type 2 diabetes","volume":"24","author":"Alqahtani","year":"2022","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102598_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jchf.2018.05.020","article-title":"Antihyperglycemic therapies to treat patients with heart failure and diabetes mellitus","volume":"6","author":"Sharma","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"24","key":"10.1016\/j.jacadv.2026.102598_bib49","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102598_bib50","first-page":"590","article-title":"Hypoglycemia and cardiac arrhythmia; mechanisms, evidence base a nd current recommendations","volume":"13","author":"Khan","year":"2016","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.jacadv.2026.102598_bib51","article-title":"Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study","volume":"354","author":"Van Dalem","year":"2016","journal-title":"BMJ Online"},{"issue":"11","key":"10.1016\/j.jacadv.2026.102598_bib52","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1002\/ejhf.1958","article-title":"Association between glycated haemoglobin levels and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the TECOS randomized clinical trial","volume":"22","author":"McAlister","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102598_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024833","article-title":"Clinical prediction models for heart failure hospitalization in type 2 diabetes: a systematic review and meta-analysis","volume":"11","author":"Razaghizad","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.jacadv.2026.102598_bib54","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:50:09Z","timestamp":1793944209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2772963X26000141"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102598","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Worsening Kidney Function and Cardiovascular Outcomes in Type 2 Diabetes and Atherosclerotic Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102598","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102598"}}